Focal nodular hyperplasia of the liver, benign hepatomas, oral contraceptives and other drugs affecting the liver.
Due to the claim of an association between focal nodular hyperplasia of the liver, benign hepatomas and oral contraceptives, the files in the departments of pathology at the university hospitals in Lund and Malmö were examined for these two diagnoses made since 1945 and 1957, respectively. 26 cases of focal nodular hyperplasia of the liver and 7 benign hepatomas were found, 18 and 2, respectively, in women. Since 1963, the year before oral contraceptives were introduced in Sweden, focal nodular hyperplasia has been diagnosed in 8 women in the reproductive period of life; 4 of these had taken oral contraceptives. The 4 diagnoses were established in 1972-1974. At most, 25 per cent of Swedish females between the ages of 15 and 44 years have been on oral contraceptives. The Swedish series of 28 patients with focal nodular hyperplasia comprised 3 epileptics and 3 diabetics. At least two of the epileptics had been treated with barbiturates and/or hydantoins. The prevalence of drug-treated epilepsy in Sweden is 0.4-0.5 per cent, and of diabetes about 2 per cent. The possible aetiological role of drugs provoking an increase of the smooth-surfaced endoplasmic reticulum of the liver and proliferation of vascular fibrous tissue in a part of the liver which preveiously may have been damaged by vascular disturbances or trauma, is considered. No relationship between benign hepatomas and drugs was found. The observations support the notion that oral contraceptives may be of aetiological importance in the development of focal nodular hyperplasia of the liver, although the material is too small for epidemiological and statistical analysis.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001463:Barbiturates / Q000009:adverse effects; D006528:Carcinoma, Hepatocellular / Q000139:chemically induced*; D056486:Chemical and Drug Induced Liver Injury; D002648:Child; D003276:Contraceptives, Oral / Q000009:adverse effects*; D004997:Ethinyl Estradiol / Q000009:adverse effects; D005260:Female; D006801:Humans; D006827:Hydantoins / Q000009:adverse effects; D006965:Hyperplasia / Q000473:pathology; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008113:Liver Neoplasms / Q000139:chemically induced* / Q000473:pathology; D008234:Lynestrenol / Q000009:adverse effects; D008297:Male; D008656:Mestranol / Q000009:adverse effects; D008875:Middle Aged
D001463:Barbiturates; D003276:Contraceptives, Oral; D006827:Hydantoins; D004997:Ethinyl Estradiol; D008656:Mestranol; D008234:Lynestrenol